Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium.
Faculty of Medicine, KU Leuven, Leuven, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Aliment Pharmacol Ther. 2023 Apr;57(8):851-860. doi: 10.1111/apt.17414. Epub 2023 Mar 1.
Functional dyspepsia (FD) is one of the most frequent conditions in gastroenterological outpatient health care. Most recent research in FD has shifted its focus to duodenal pathophysiological mechanisms, although current treatments still focus mainly the stomach.
The aim of the study was to provide a comprehensive overview of the pathophysiology of FD focusing on a paradigm shift from gastric towards duodenal mechanisms.
We conducted a literature search in PubMed for studies describing mechanisms that could possibly cause FD.
The pathophysiology of FD remains incompletely understood. Recent studies show that duodenal factors such as acid, bile salt exposure and eosinophil and mast cell activation correlate with symptom pattern and burden and can be associated with gastric sensorimotor dysfunction. The evolving data identify the duodenum an interesting target for new therapeutic approaches. Furthermore, the current first-line treatment, that is proton pump inhibitors, reduces duodenal low-grade inflammation and FD symptoms.
Future research for the treatment of FD should focus on the inhibition of duodenal mast cell activation, eosinophilia and loss of mucosal integrity.
功能性消化不良(FD)是消化科门诊最常见的病症之一。FD 的最新研究重点已转移到十二指肠的病理生理机制上,尽管目前的治疗方法仍主要针对胃部。
本研究旨在全面概述 FD 的病理生理学,重点关注从胃部机制向十二指肠机制的范式转变。
我们在 PubMed 上进行了文献检索,以查找可能导致 FD 的机制的研究。
FD 的病理生理学仍不完全清楚。最近的研究表明,十二指肠因素如胃酸、胆汁盐暴露以及嗜酸性粒细胞和肥大细胞激活与症状模式和负担相关,并可能与胃感觉运动功能障碍有关。不断发展的数据将十二指肠确定为新治疗方法的一个有趣靶点。此外,目前的一线治疗药物质子泵抑制剂可降低十二指肠低度炎症和 FD 症状。
未来 FD 的治疗研究应侧重于抑制十二指肠肥大细胞激活、嗜酸性粒细胞增多和黏膜完整性丧失。